Takuya Adachi

Okayama, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

CLEIA-based type IV collagen 7S for second-step assessment of MRE-defined clinically significant fibrosis in MASLD with indeterminate FIB-4.

CLEIA-based type IV collagen 7S for second-step assessment of MRE-defined clinically significant fibrosis in MASLD with indeterminate FIB-4.

Journal: Scientific reports
Published: May 06, 2026

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: April 03, 2026

Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.

Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.

Journal: JHEP reports : innovation in hepatology
Published: March 27, 2026

Metastatic Intraocular Tumor Likely from Hepatocellular Carcinoma Mimicking Panuveitis.

Metastatic Intraocular Tumor Likely from Hepatocellular Carcinoma Mimicking Panuveitis.

Journal: Acta medica Okayama
Published: February 26, 2026

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.

Journal: Journal of gastroenterology
Published: February 21, 2026

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: November 07, 2025

Nationwide comprehensive genomic profiling defines the genomic landscape of hepatocellular carcinoma across etiologies.

Nationwide comprehensive genomic profiling defines the genomic landscape of hepatocellular carcinoma across etiologies.

Journal: Scientific reports
Published: August 21, 2025

Clinical Variables That Predict Liver-related Events in Steatotic Liver Disease Diagnosed by a Liver Biopsy.

Clinical Variables That Predict Liver-related Events in Steatotic Liver Disease Diagnosed by a Liver Biopsy.

Journal: Internal medicine (Tokyo, Japan)
Published: February 09, 2025

Local Control of Conjunctival Malignant Melanoma by Proton Beam Therapy in a Patient With No Metastasis in Six Years From in Situ to Nodular Lesions.

Local Control of Conjunctival Malignant Melanoma by Proton Beam Therapy in a Patient With No Metastasis in Six Years From in Situ to Nodular Lesions.

Journal: Journal of medical cases
Published: October 22, 2024

Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".

Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".

Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 21, 2024

Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.

Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.

Journal: Gastro hep advances
Published: November 14, 2023

Disease Progression-Related Markers for Aged Non-Alcoholic Fatty Liver Disease Patients.

Disease Progression-Related Markers for Aged Non-Alcoholic Fatty Liver Disease Patients.

Journal: Acta medica Okayama
Published: August 27, 2023
Showing 1-12 of 34

Last Updated: 09/26/2026